Skip to main content
Careers

About Bard

 

Since 1907, C. R. Bard Inc., has been developing innovative medical technologies that have become cornerstones of modern healthcare. Bard has pioneered such devices as the Foley catheter, the heart-pacing catheter, the arterial prosthesis and the angioplasty catheter.

Today, we are a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of:

  • Vascular
  • Urology
  • Continence
  • Oncology
  • Surgical Specialty

Employing over 16,000 people globally, the Bard Limited Head Office is based in Crawley, West Sussex.


View Our Historical Timeline

What drives us

Our core values of Quality, Integrity, Service, and Innovation are central to how we work. Watch the videos to get to know a little more about us, our focus, and our history.

Our Mission

To advance lives and the delivery of healthcare by profitably developing, manufacturing and marketing value-driven products which meet the quality, integrity, service, and innovation expectations of our customers while providing opportunities for our employees.  As a result, we will optimize shareholder value and be a respected worldwide health care company.

A Long History of Technological Innovation

1900s
1920s
1930s
1940s
1950s
1960s
1970s
1980s
1990s
2000s
2010s
Charles Russell Bard, founder of C.R. Bard

1907

Charles Russell Bard (pictured) was an American importer of French silks. In 1907, he begins importing Gomenol in New York City.

1907

Gomenol, a European cure-all, helped relieve Mr. Bard's urinary discomfort from tuberculosis.

1923

C.R. Bard, Inc. is formally incorporated.

1925

BARD publishes its first product catalog.

John F. Willits and Edson L. Outwin

1926

Charles Russell Bard sells business to John F. Willits (pictured left), Sales Manager, and Edson L. Outwin (pictured right), Accountant, for $18,000.

Harris L. Willits

1929

Harris L. Willits (pictured) joins the BARD staff as a sales representative.

Charles Russell Bard, founder of C.R. Bard, Inc.

1934

Company founder Charles Russell Bard dies.

Davol Rubber Company historic illustration and patent application

1934

Davol Rubber Company of Providence, Rhode Island begins to manufacture the Foley catheter.BARD becomes the exclusive distributor for the Foley catheter and other Davol latex catheters.

Pictured: The Davol Rubber Company in 1934, and an illustration accompanying Davol Rubber Company's 1935 patent application for a rubber catheter invented by Paul A. Raiche, anexperimental engineer.

1940

Norman Jeckel develops the first American woven catheter and the machinery to manufacture it. He establishes the U.S. Catheter & Instrument Corporation (USCI) in Glens Falls, New York. Bard begins to distribute Jeckel's new catheter.

1945

Harris L. Willits becomes a member of the Board of Directors.

1948

BARD moves from New York City into a new building in Summit, New Jersey, and in 1949 the first BARD sales meeting is held at headquarters with representatives from Davol & USCI.

Dr. DeBakey

1954

Dr. DeBakey (pictured) develops the first arterial prosthesis.

Harris L. Willits

1955

Harris L. Willits (pictured) is elected President of BARD.

Edson L. Outwin, James Vassar, Harris Willits, and Edson S. Outwin at Canoe Brook Country Club in 1957

1957

Bard celebrates its 50th anniversary, marking five decades of dedication to the medical profession. Pictured left to right: Edson L. Outwin, James Vassar, Harris Willits, and Edson S. Outwin at Canoe Brook Country Club in December 1957.

1958 Bardex Foley catheter advertisement

1958

Bard introduces a pre-sterilized packaged Foley catheter and has a sterilizer built to start handling in-plant sterilization. Pictured: A 1958 Bardex Foley catheter advertisement explains how sterilized, packaged products can save customers time and money and also provide convenience since they are ready for instant use. 

Historical photo of C.R. Bard, Inc. headquarters in Murray Hill, NJ

1961

Bard moves into a new one-story 50,000 square foot building in Murray Hill, New Jersey (pictured). The larger facility allowed the company to centralize its offices.

BARD employee at Glens Falls, NY plant inspecting coronary catheters

1961

Bard begins to extend its efforts beyond the urology market into cardiology, radiology and anesthesiology.

Pictured: A Bard employee at the Glens Falls, New York, plant inspects coronary catheters produced by Bard's USCI Cardiology and Radiology Division.

Medical supply storage at BARD’s Bridgewater, NJ location and in-house sterilization operations

1964

Bard establishes its first in-house manufacturing operation — producing the molding and assembling of medical plastic tubing.
 
Pictured, left: Sterile and disposable medical supplies are stacked high at Bard's plant in Bridgewater, New Jersey, in the early 1960s.
 
Pictured, right: The introduction of in-house sterilization operations in 1964 greatly expanded Bard’s manufacturing capabilities since laborsaving devices such as pre-sterilized hospital supplies had become a necessity rather than a luxury in the 1960s.

1965

Bard announces a 3-for-2 stock split.

Roland F. Simons

1966

Harris L. Willits becomes Chairman of the Board. Roland F. Simons (pictured) is elected President. Simons was instrumental in increasing BARD's research and development programs throughout the 1960s.

1966

BARD and USCI merge, cementing a 25 year association.

1967

BARD builds a 100,000 square foot plant in Covington, Georgia, geographically expanding its manufacturing and warehousing operations.

1967

BARD announces a 2-for-1 stock split.

1968

J. Wendell Crain is elected President.

1968

Bard's capital stock is listed and traded on the New York Stock Exchange under the symbol "BCR".

Technicians at BARD subject samples of urological products to USP sterility testing

1968

Bard builds a 172,000 square foot manufacturing plant at the Murray Hill, New Jersey location.
 
Pictured: Technicians at Bard's New Jersey facilities subject samples of urological products to United States Pharmacopeia (USP) sterility testing, upholding the company's commitment to the highest product quality.

Harris L. Willits

1971

Harris L. Willits is elected to honorary membership in the Medical Surgical Manufacturers Association, a distinction awarded only six other people.

Jay Bhaat, manager of BARD Japan in 1977, speaks at a USCI seminar; BARD’s Medicon unit

1972

Bard joins with Kobayashi Pharmaceutical Company, Ltd. of Japan in establishing what is now known as Medicon, Inc., to import and market Bard products in Japan and form new joint ventures with international manufacturers.
 
Pictured, left: Jay Bhatt, Bard's Japan manager in 1977, speaks at a USCI Division seminar in Tokyo, Japan.
 
Pictured, right: With new leadership, Bard's Medicon unit saw fresh opportunities for business as Japan changed to diagnosis-based reimbursement. Indeed, sales grew by 27 percent in 2004. Pictured from left to right are K. Minato, Y. Sakai, and T. Kashiwagi.

1972

BARD announces a 2-for-1 stock split.

BARD inspector in Santa Ana, CA examines components of blood oxygenators

1975

Bard acquires the William Harvey Research Corporation, expanding cardiopulmonary products for open-heart and bypass surgery.
 
Pictured: An inspector at the Santa Ana, California, plant examines components of William Harvey blood oxygenators used for cardiothoracic surgery.

1976

Robert H. McCaffrey is elected Director and President.

Robert H. McCaffrey, Harris Willits and George Maloney

1978

Robert H. McCaffrey is elected Chairman of the Board and Chief Executive Officer. George T. Maloney is elected President and Chief Operating Officer.
 
Pictured, from left to right: Over the years, Robert McCaffrey, Harris Willits, and George Maloney developed a friendly corporate culture, which many Bard employees welcomed with gratitude.

1978

Harris L. Willits is elected Honorary Chairman.

Doctor using BARD’s USCI catheter system

1979

Bard obtains the exclusive rights to manufacture and market the Gruntzig catheter, a balloon-tipped angioplasty catheter giving surgeons a safer and less costly alternative to open-heart surgery.
 
Pictured: Using one of Bard's USCI catheter systems, a doctor prepares for an angioplasty procedure in a catheterization laboratory.

Historical photography of Davol, Inc. location

1980

After a 46-year association, BARD acquires Davol Inc. (pictured), with its Foley catheter manufacturing facilities in Moncks Corner, South Carolina and Clacton-On-Sea, England.

1982

BARD announces a 3-for-2 stock split.

1984

BARD sets up manufacturing plant in Nogales, Mexico.

1984

BARD acquires Evermed, creating the platform for the Bard Access Systems franchise.

1985

A joint venture, Bard Bio-Spectrum Pty. Ltd., is created in Australia.

1986

BARD announces a 2-for-1 stock split.

Laboratories Bard in Paris; a cardiologist in the lab of Policlinico Umberto

1988

Bard Europe is formed by merging Bard UK/Europe with USCI International.

Pictured, left: A cardiologist in the laboratory of Policlinico Umberto in Rome, Italy, examines Bard Simplus and Probe angioplasty catheters in 1988. Courtesy of John Zoiner Photography. 
 
Pictured, right: The headquarters of Laboratories Bard in the Paris suburb of Gentilly, France. 

Edward A. Leskanic, David W. Prigmore, and Laurence E. Lindars. Seated: George A. Davis, William G. Little, Terence C. Brady Jr., George T. Maloney, and Robert H. McCaffrey

1988

Bard's 1985 Management Executive Committee guided the company's divisions to operate as entrepreneurial units and remain organized around market specialization. Pictured from left to right, standing: Edward A. Leskanic, David W. Prigmore, and Laurence E. Lindars. Seated: George A. Davis, William G. Little, Terence C. Brady Jr., George T. Maloney, and Robert H. McCaffrey. Courtesy of Bill Ray Photography.

George T. Maloney greets visitors at C.R. Bard’s annual meeting

1989

George T. Maloney (pictured, greeting visitors at Bard’s annual meeting) is elected President and Chief Executive Officer. His friendly and personable nature, as well as his problem-solving skills and sharp mind, earned him a solid reputation for more than three decades with the company.

An I.V. nurse discusses cathether placement at a patient’s bedside with BARD employees

1989

Bard acquires Catheter Technology Corporation, Salt Lake City, Utah, strengthening Bard's position in the vascular access devices market. This becomes the divisional headquarters for Bard Access Systems, Inc. in 1991.
 
Pictured: An I.V. nurse at Christ Hospital in Cincinnati, Ohio, discusses catheter placement at a patient's bedside with Bard Access Systems employees.

1991

Bard Electrophysiology Division is formed.

George T. Maloney

1991

George T. Maloney (pictured) is elected Chairman of the Board and Chief Executive Officer.

1992

Bard Bio-Spectrum Pty. Ltd. becomes Bard Australia.

1992

Harris L. Willits, Honorary Chairman, dies.

1994

William Longfield (pictured) is elected President and Chief Executive Officer.

1994

BARD acquires Angiomed AG (biliary stent).

BARD Corporate Healthcare Services logo

1994

Corporate Healthcare Services organization is established.

1995

William Longfield is elected Chairman of the Board.

1996

BARD acquires IMPRA, Inc. (vascular prosthetics).

A quality assurance auditor at Bard FiberOptic Technologies; the BARDEX Lubricath Foley catheter

1996

Bard Medical Division is formed. 

Pictured, left: Bard FiberOptic Technologies in Ann Arbor, Michigan, which manufactured high-tech urological monitoring devices using fiber optics, added to the company's technological revolution in the late 1990s. Here, quality assurance auditor Donna Reese performs an inspection.  

Pictured, right: The BARDEX® Lubricath Foley catheter is a late 1990s update of the Foley catheter, Bard's trademark product.

A BARD employee conducts flow tests on PDLC

1996

Bard enters joint venture agreement with Pacific Healthcare in Taiwan. Bard opens sales offices in China, Korea and Singapore.
 
Pictured: At Bard, new product development and incremental product improvement is a continuous process. Bard employee Hong le Nguyen conducts flow tests on PDLC.

1998

BARD divests USCI cardiology division, cardiac assist & cardiopulmonary business units.

A BARD employee assembles the rod for a dual lumen wing retainer

1999

Bard acquires Dymax Inc. an ultrasound technology for placing catheters.
The 1994 Vas-Cath acquisition helped Bard expand its dialysis catheter and peripheral balloon angioplasty catheter product lines.
 
Pictured: Bard employee Lena Diaz assembles the rod for a dual lumen wing retainer.

2000

Bard acquires the assets of Surgical Sense, Inc. and its Kugel® patch product line.

Timothy M. Ring and John Weiland

2003

Timothy M. Ring (pictured, left) is elected Chairman of the Board and Chief Executive Officer. John Weiland (pictured, right) is elected President and Chief Operating Officer. Both were groomed by predecessor William Longfield to continue growing Bard in the 21st century. In their first full year running the company, net sales grew by 13 percent in constant currency.
 
Courtesy of Gloria Baker Photography.

Luminexx vascular stent; Ventralex hernia patch

2003

Bard Peripheral Vascular subsidiary is formed.

Pictured top: Luminexx™ vascular stent

Pictured, bottom: Ventralex® Hernia patch. Courtesy of Gloria Baker Photography.

2003

Bard acquires vacuum-assisted biopsy device technology from Biomedical Instruments and Products GmbH.
 

Successful BARD patient Herman Herndon, treated with ProSeed Brachytehrapy service

2003

Bard acquires SourceTech Medical, L.L.C., an iodine radioactive isotope seed business for Brachytherapy
 
Pictured: Hunter Herndon, of Midlothian, Virginia, buffs the wheel of his vintage 1934 Ford Coupe. Herndon was able to quickly return to his normal activities after undergoing treatment for prostate cancer with Bard's ProSeed® Brachytherapy service, which places tiny radioactive seeds guided by ultrasound into the prostate gland.
 
Courtesy of Gloria Baker Photography.
 

2004

Bard acquires assets of ONUX Medical and its Salute® fixation system for hernia and soft tissue repair.

BARD worldwide operations team

2004

Bard announces 2-for-1 stock split.
 
In 2003, Bard's worldwide operations team spearheaded improvements that increased profit margins by 3.2 percentage points. Pictured clockwise from top left are Mark Walaska, staff vice president of manufacturing; Frank Maloit, staff vice president for corporate procurement; Scott Mummert, director for operational excellence; Kevin Phoenix, director of facilities; John Moran, staff vice president for manufacturing projects; Ted Doorley, staff vice president for manufacturing; and Joe Cherry, vice president of operations.
 
Courtesy of Gloria Baker Photography.

2005

Bard acquires assets of Genyx Medical, including the TegressT implantable bulking agent for the treatment of stress urinary incontinence.

2006

Bard acquires Venetec International, Inc., manufacturer of the StatLock® line of catheter securement devices.

BARD 100th anniversary seal

2007

Bard celebrates 100 year milestone.

Bard LifeStent

2008

Bard acquires LifeStent® (pictured) from Edwards Lifesciences which is marketed by Bard’s Peripheral Vascular Division, Tempe Arizona.

2009

Bard receives FDA PMA approval of LifeStent® for SFA (superficial femoral arteries) indication.

2010

In the largest acquisition to date, Bard acquires SenoRx, Inc., providing Bard leadership products across all breast biopsy and marker segments.

Medivance Arctic Sun

2011

Bard acquires Medivance, Inc., the market leader in the field of therapeutic hypothermia. Medivance's Arctic Sun® family of products provides clinicians with a powerful technology to effectively manage patient temperature in a non-invasive manner.

Lutonix transliminal angioplasty (PTA) balloon

2011

Bard acquires Lutonix, Inc., developer of a drug-coated percutaneous transluminal angioplasty (PTA) balloon. Lutonix is the first to conduct the only investigational device exemption (IDE) trial approved by the FDA using drug-coated balloons for the treatment of peripheral arterial disease.

Neomend logo

2012

Bard acquires privately-held Neomend, Inc., a leading developer and supplier of sprayable surgical sealants and anti-adhesion products.  This merger significantly expands the business opportunities for Bard surgical specialties in the Davol subsidiary.

Medafor Arista MPH hemostat

2013

Bard acquires Medafor, Inc., a leading developer and supplier of plant based hemostatic agents. Medafor’s Arista® MPH Hemostat, is indicated as an adjunctive hemostatic agent to control bleeding when conventional means are ineffective or impractical. The acquisition expands the business opportunities for Bard’s surgical specialties in its Davol subsidiary.

BARD electrophysiology logo

2013

Bard divests Electrophysiology business and sells certain assets to Boston Scientific Corporation. 

2013

Bard acquires Rochester Medical, Inc., a leading developer and supplier of silicone urinary incontinence and urine drainage products. The merger represents a compelling strategic fit that enhances Bard’s position in the global urology homecare market.

Lutonix 035 drug coated balloon

2014

The Lutonix® 035 Drug Coated Balloon is the first FDA-Approved Drug Coated Balloon available in the U.S. for the Treatment of Femoropopliteal Occlusive Disease. The Lutonix® 035 DCB is an angioplasty balloon coated with a therapeutic dose of the drug paclitaxel, and also utilizes standard mechanical dilatation of the vessel to restore blood flow for patients with peripheral arterial disease (PAD) in the femoropopliteal arteries.

XenMatrix AB surgical graft antibacterial-coated regenerative collagen matrix

2014

XENMATRIX™ AB Surgical Graft Antibacterial-Coated Regenerative Collagen Matrix is the first antibacterial-coated, non-crosslinked porcine dermal graft proven to inhibit the graft colonization of MRSA, E. coli, and other bacteria in preclinical models.1,2  It uses a combination of well-characterized antibotiotics, Rifampin and Minocycline, to offer an unmatched level of graft protection in challenging ventral hernia repair.
 
1. IMS Data, Q2 2014, 550K search, fda.gov.  
2. Preclinical data on file; results may not correlate to clinical performance.
 

2015

Bard acquires full ownership of its joint venture, Medicon, Inc., in Japan.

2016

Bard acquires Liberator Medical Holdings, Inc.  Liberator is a direct-to-consumer distributor of medical products classified as Durable Medical Equipment (DME).